Home/Polygon Therapeutics/Prof. Nicolas Danchin

PN

Prof. Nicolas Danchin

Scientific Board Member

Polygon Therapeutics

Therapeutic Areas

Cardiovascular Immunology

Polygon Therapeutics Pipeline

Drug	Indication	Phase
PLG-101 (EMOTION Program)	Acute Myocardial Infarction (Heart Attack)	Pre-clinical

Leadership Team at Polygon Therapeutics

Mohamed Abou Ali

Chief Executive Officer & Co-founder

Pr. Hafid Ait Oufella

Chief Scientific Officer & Co-founder

Tatiana Monseur

Chief Operating & Financial Officer & Co-founder

Prof. Peter Libby

Scientific Board Member

View full Polygon Therapeutics profile